dfda compounded glp-1 receptor agonists FDA issued 25 warning letters to telehealth companies for false and misleading claims about products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of GLP-1 Drugs from the Gray

Glycemic monitoring with CGMs, glucose-lowering agents (GLP-1 receptor agonists), innovative insulin delivery systems, and mental health check-ins are just a few updates to the ADA 2025 Standards of Care.

Learn the pros, cons, effectiveness, risks, and who each option is best suited for.

This breakthrough formula fires up GLP-1 production to fend off cravings, especially those carb-loaded temptations

The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.

Sarah Mess.

The incretin hormone glucagon-like peptide 1 (GLP-1) has been implicated in the gutrenal axis and incretin-based therapies might reduce the burden of diabetic kidney disease